Novartis CEO Narasimhan Is Encouraged On US Drug Pricing Ahead Of Trump's Announcement

New CEO offers his perspective on potential US drug pricing policy changes, including changes to Medicare Part B and pricing transparency. Pharma must also think more about social responsibility, he says, wading into a topic that will certainly be an issue for the new generation of industry leaders.